3-Methylcrotonyl-CoA carboxylase deficiency (3-MCC)
Log in to starLast updated Nov 4, 2026
A newborn screen flags an elevated C5-hydroxyacylcarnitine (C5-OH). The baby is feeding well and examining normally. Confirmatory testing on the infant is equivocal, and testing the mother shows the same biochemical abnormality: she has 3-MCC deficiency herself, has always been asymptomatic, and was identified only because her baby was screened.
- Autosomal recessive, MCCC1 and MCCC2, the alpha and beta subunits of 3-methylcrotonyl-CoA carboxylase, a biotin-dependent carboxylase in leucine catabolism; biallelic variants reduce or abolish its activity
- One of the most frequently detected disorders on expanded newborn screening, at roughly 1 in 30,000 to 1 in 50,000
- The great majority of people identified are and remain asymptomatic. This is the defining fact about the condition and the reason it is counselled differently from other organic acidemias
3-methylcrotonyl-CoA carboxylase (MCC) is a mitochondrial, biotin-dependent enzyme that catalyzes the fourth step of leucine breakdown. It is a 12-subunit complex: the alpha subunit (MCCC1) carries the biotin carboxylase domain and the bound biotin, and the beta subunit (MCCC2) carries the carboxyltransferase domain. Biallelic variants in either gene severely reduce or abolish activity; most are missense, with small insertions and deletions, nonsense, frameshift, and splice variants.
Leucine intermediates back up and leave as 3-hydroxyisovaleric acid and 3-methylcrotonylglycine in urine and C5-OH in blood. Many patients, including babies found by screening, also develop secondary carnitine deficiency, which is why free carnitine is monitored.
Penetrance is low, and neither genotype nor residual activity predicts the course: adults homozygous for null variants can be asymptomatic, and siblings with the same genotype can differ, which points to environmental triggers. MCCC1 p.Arg385Ser, the most common variant in one large series, acts as a dominant negative and may cause biochemical and clinical abnormalities in heterozygotes.
Part of branched-chain amino acid catabolism.
Leucine catabolism (branched-chain amino acid breakdown, the leucine branch).
leucine → isovaleryl-CoA → isovaleryl-CoA dehydrogenase → 3-methylcrotonyl-CoA → 3-methylcrotonyl-CoA carboxylase (the block; biotin cofactor) → 3-methylglutaconyl-CoA → HMG-CoA → acetoacetate, acetyl-CoA
- Accumulates: 3-methylcrotonyl-CoA and its products, measured as C5-OH (3-hydroxyisovalerylcarnitine) on newborn screening and 3-hydroxyisovaleric acid and 3-methylcrotonylglycine in urine; free carnitine is often low.
- Missing: the later leucine products, which rarely matters, since most people stay well.
- Usually no features at all. Most are ascertained through newborn screening or, as above, through their own child's screen
- A minority decompensate under catabolic stress, typically an intercurrent illness with poor intake, with hypoglycemia, metabolic acidosis, hyperammonemia, vomiting and lethargy
- Reported in a small subset: developmental delay, seizures, hypotonia, failure to thrive. Whether these are caused by the enzyme deficiency or are coincidental in an ascertained population remains genuinely unsettled
- Maternal 3-MCC deficiency is a recognised cause of a positive newborn screen in an unaffected baby, because maternal metabolites cross the placenta
- Elevated C5-OH acylcarnitine on newborn screening
- Urine organic acids: 3-hydroxyisovaleric acid and 3-methylcrotonylglycine, the specific marker
- Plasma free carnitine is often low
- Confirm with MCCC1 and MCCC2 sequencing
- If the infant's confirmatory testing is normal or equivocal, test the mother
The C5-OH differential, which is the real teaching point
An elevated C5-OH is not specific, and two of its causes are treatable in a way 3-MCC is not:
| Cause | Distinguishing feature |
|---|---|
| 3-MCC deficiency | 3-methylcrotonylglycine; usually benign |
| Biotinidase deficiency | Low serum biotinidase enzyme activity; treat with biotin |
| Holocarboxylase synthetase deficiency | Neonatal onset, normal biotinidase activity; treat with biotin |
| 3-methylglutaconic aciduria | 3-methylglutaconic and 3-methylglutaric acids |
| HMG-CoA lyase deficiency | 3-hydroxy-3-methylglutaric acid; hypoketotic hypoglycemia |
| Beta-ketothiolase deficiency | 2-methyl-3-hydroxybutyrate, tiglylglycine |
- Avoid prolonged fasting, with an age-appropriate fasting limit and a written sick-day plan
- Emergency regimen with intravenous dextrose during illness, which is the intervention that actually prevents the rare crises
- Carnitine supplementation when free carnitine is low
- Leucine restriction is not routinely needed and is reserved for the symptomatic minority
- Counsel the family honestly: most individuals with this diagnosis never have a metabolic event, and the label carries a risk of unnecessary alarm
- Work down the C5-OH differential before settling on 3-MCC, because biotinidase and holocarboxylase synthetase deficiency are both biotin-responsive and both cause permanent harm if missed. 3-MCC is the common answer, but it is the one that matters least.
- A positive newborn screen with a well baby and equivocal confirmation should prompt testing the mother. Maternal 3-MCC deficiency is the classic explanation and is frequently how an asymptomatic adult is diagnosed.
- This is the cleanest example in newborn screening of a condition where detection outruns clinical significance, which is worth saying plainly to families.